Continuation of trastuzumab beyond disease progression - Reply

被引：4

作者：

Hortobagyi, GN ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 12期

关键词：

D O I：

10.1200/JCO.2005.05.300

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2868 / 2869

页数：2

共 10 条

[1]

[Anonymous], CLIN BREAST CANC

[2] Evidence from randomised trials on the long-term effects of hormone replacement therapy [J].

Beral, V ;

Banks, E ;

Reeves, G .

LANCET, 2002, 360 (9337) :942-944

[3] Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: A phase III randomized trial [J].

Byrne, MJ ;

Gebski, V ;

Forbes, J ;

Tattersall, MHN ;

Simes, RJ ;

Coates, AS ;

Dewar, J ;

Lunn, M ;

Flower, C ;

Gill, PG ;

Stewart, J .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (09) :3141-3148

[4]

Gelmon Karen A, 2004, Clin Breast Cancer, V5, P52, DOI 10.3816/CBC.2004.n.010

[5]

Hortobagyi GN, 1999, J CLIN ONCOL, V17, P25

[6] 2ND-LINE HORMONOTHERAPY FOR BREAST-CANCER - USELESSNESS OF 1ST-LINE CONTINUATION [J].

PRONZATO, P ;

RUBAGOTTI, A ;

AMOROSO, D ;

BERTELLI, G ;

QUEIROLO, P ;

SERTOLI, MR ;

ROSSO, M ;

GALLOTTI, P ;

MONZEGLIO, C ;

ROSSO, R .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1993, 16 (06) :522-525

[7]

ROSNER D, 1987, CANCER, V59, P874, DOI 10.1002/1097-0142(19870301)59:5<874::AID-CNCR2820590503>3.0.CO

[8]

2-O

[9] The basic biology of HER2 [J].

Rubin, I ;

Yarden, Y .

ANNALS OF ONCOLOGY, 2001, 12 :3-8

[10] Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression [J].

Tripathy, D ;

Slamon, DJ ;

Cobleigh, M ;

Arnold, A ;

Saleh, M ;

Mortimer, JE ;

Murphy, M ;

Stewart, SJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1063-1070

← 1 →